Companies: 10,795·Total market cap: $144.5T
ImmunityBio, Inc.

ImmunityBio, Inc.

IBRXNASDAQHealthcare● Active
$7.17
+$0.25(+3.61%)
Market Cap$7.5B
P/E Ratio—
52W High$12.43
52W Low$1.95
Overview

ImmunityBio, Inc. (IBRX) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

IBRX · net income · updated Jun 8, 2026

Core profitability metrics

Net income was −$351.4M for FY2025 (fiscal year ending 2025-12-31), up 15.0% year-over-year. Net profit margin was -310.2%.

FY2025 Net Income−$351.4M▲ +15.0% YoY
Trailing 12M (TTM)−$854.5Mtrailing 4 quarters sum
Net Profit Margin-310.2%−$351.4M ÷ $113.3M
YoY Change+15.0%—
5-Year CAGRN/AN/A — contains loss years
FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0
Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · IBRX net income history · IBRX profit margin

Annual net income data

Fiscal YearNet IncomeYoY ChangeNet Margin
FY2025Loss−$351.4M▲ +15.0%-310.2%
FY2024Loss−$413.6M▲ +29.1%-2804.8%
FY2023Loss−$583.2M▼ 40.0%-93761.4%
FY2022Loss−$416.6M▼ 20.1%-173569.6%
FY2021Loss−$346.8M▼ 56.3%-37129.6%

Net income vs peers (Healthcare)

#CompanyNet IncomeYoY
#1
ImmunityBio, Inc.
ImmunityBio, Inc.YOU
IBRX
−$351.4M+15.0%
#2
Johnson & Johnson
Johnson & Johnson
JNJ
$26.80B+90.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$20.64B+94.9%#4
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$12.06B-16.3%#5
AbbVie Inc.
AbbVie Inc.
ABBV
$4.23B-1.2%
Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

ImmunityBio, Inc. (IBRX) reported net income of −$351.4M for FY2025 (fiscal year ending 2025-12-31), up 15.0% year-over-year. The net profit margin was -310.2% — meaning the company kept $-3.10 of every dollar of revenue as profit.

ImmunityBio, Inc. has not yet achieved annual profitability based on available data (13 fiscal years). The company has reported net losses across all available periods.

ImmunityBio, Inc.'s net profit margin was -310.2% for FY2025, based on the latest annual results.

Investors sometimes search for "ImmunityBio, Inc. net worth" — the company's market capitalization is a separate figure from IBRX net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.
RevenueFinancial statementsEarningsForecastPrice historyMarket capFree cash flow

Frequently asked questions

IBRX net income · 4 questions

ImmunityBio, Inc. is not currently profitable on an annual basis. The company reported a net loss of $351.4M for FY2025.

is IBRX profitabledoes IBRX make a profitIBRX profitabilityIBRX profitable company

▸ Source: FMP /income-statement · GAAP · ImmunityBio, Inc. · ImmunityBio, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026